louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00306371: Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser
Official title: Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acne
Acne Scars
Keywords: diode
laser
acne
acne scar
Lead sponsor: Skincare Physicians of Chestnut Hill
Sponsor class: OTHER
Collaborators: name: Candela Corporation
First posted: 2006-03-23
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: Acne can be treated with a mid-infrared laser. We demonstrated safety and efficacy using lower energy settings in order to make the treatments less painful

Detailed description: Numerous light based therapies are currently being used for the treatment of acne. Non-ablative mid-infrared lasers have the advantage of decreasing inflammatory acne and improving acne scars. Specifically, the 1450 nm laser has been shown to be quite effective. However, it is associated with considerable pain at higher fluences despite topical anesthetics, especially when treating inflammatory acne. The goal of this study was to determine the possibility of using low fluence settings to treat moderate to severe acne at a more tolerable pain level without compromising treatment effectiveness.

Eligibility criteria: Inclusion Criteria:

* acne lesion count of at least 10 inflammatory papules on each side of the face and a severity grade consistent with color photographs in the Allen \& Smith grading scale of greater than or equal to grade 3 and no worse than grade 5

Exclusion Criteria:

* Exclusion criteria included the use of oral retinoids or systemic corticosteroids within the past 6 months and the use of all prescription topical or systemic anti-acne medications 4 weeks prior to the initiation of the study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chestnut Hill
country: United States
facility: Skincare physicians of Chestnut Hill
state: Massachusetts
Study officials:
affiliation: Skincare Physicians of Chestnut Hill
name: Nathan S Uebelhoer, DO
role: PRINCIPAL_INVESTIGATOR
affiliation: Skincare Physicians of Chestnut Hill
name: Jeffrey S Dover, MD
role: STUDY_DIRECTOR
affiliation: Skincare Physicians of Chestnut Hill
name: Kenneth A Arndt, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01872871: The Efficacy of Paracetamol in Reducing Pain During Ophthalmological Examination for Retinopathy of Prematurity: a Prospective Randomised Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Retinopathy of Prematurity
Lead sponsor: Dr. Sami Ulus Children's Hospital
Sponsor class: OTHER
First posted: 2013-06-07
Enrollment: 80
Sex: ALL
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Retinopathy of prematurity (ROP) is one of the major morbidity among preterm infants. Although, local anesthetics reduce pain to some extent, eye examination still remains as a painful procedure. The investigators aimed to evaluate the effect of oral paracetamol combined with local anesthetics for pain relief during ophthalmological examination.


Eligibility criteria: Inclusion Criteria:

* gestational age below 32 weeks or birth weight below 1500 grams

Exclusion Criteria:

* congenital anomalies, necrotising enterocolitis, surgical problems

Primary outcomes:
measure: Reducing pain assessment score
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Dr. Sami Ulus Childrens Hospital
Study officials:
References:
citation: Allegaert K, Tibboel D, Naulaers G, Tison D, De Jonge A, Van Dijk M, Vanhole C, Devlieger H. Systematic evaluation of pain in neonates: effect on the number of intravenous analgesics prescribed. Eur J Clin Pharmacol. 2003 Jun;59(2):87-90. doi: 10.1007/s00228-003-0585-3. Epub 2003 Apr 4.
Clinical trial NCT03220971: Lipoprotein and Apolipoproteins With Metabolic Liver Diseases
Official title: Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Disorders of Lipoprotein Metabolism and Other Lipidaemias
Keywords: Lipoprotein and Apolipoproteins metabolism
Lead sponsor: Tainan Municipal Hospital
Sponsor class: OTHER
First posted: 2017-07-18
Enrollment: 440
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression. Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders

Brief summary: Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad

Detailed description: An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression. Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders

Eligibility criteria: Inclusion Criteria:

1. above 20 years
2. nonalcoholic fatty liver disease
3. Non-Alcoholic Steatohepatitis

Exclusion Criteria:

1. alcohonic hepatitis 2. Autoimmune liver disease 3. HIV postive

-

Primary outcomes:
measure: Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad
timeFrame: 2years
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Chun-Hsiang Wang
Study officials:
References:
Clinical trial NCT05566171: The Effect of Probiotic Supported Yogurt Consumption on Gastrointestinal Symptoms
Official title: The Effect of Probiotic Supported Yogurt Consumption on Gastrointestinal Symptoms Among People Aged 19-64 Years
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Gastrointestinal Dysfunction
Keywords: probiotic, gastrointestinal symptoms, constipation
Lead sponsor: Eastern Mediterranean University
Sponsor class: OTHER
First posted: 2022-10-04
Enrollment: 102
Sex: ALL
Minimum age (years): 19
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Probiotics have beneficial effect on Gastrointestinal Symptoms. The aim of this study is to determine the effect of probiotic yogurt consumptions on the people who have gastrointestinal symptoms mainly constipation.

Detailed description: In the beginning of the study Constipation Severity Scale and Bristol Stool Scale was applied to the all people who accepted to participate in this study. According to the student T test analysis (α= 0.05, β=0.20 ) 102 people with gastrointestinal symtoms should be included in the study. When 102 people are found with gastrointestinal symptoms second stage of the study will begin. In this stage of the study 102 people are randomly divided into 2 homogeneous groups. 3 day food record will be taken from 102 people at the beginning and again at the end of the study. Probiotic yogurt (Activia Probiotic Yogurt without any aroma-125 g) will be given to one group for 1 month and nothing will be given to the other group (control group).

Eligibility criteria: Inclusion Criteria:

* Living in Izmir
* Individuals who are having BMI between 18.5-24.9 kg / m2
* Having gastrointestinal symptoms according to Constipation Severity Scale and Bristol Stool Scale

Exclusion Criteria:

* Having diagnosed gastrointestinal disease
* Regular consumption of probiotic
* Using of drug that affects gastrointestinal system
* Presence of mental illness

Primary outcomes:
measure: The severity of gastrointestinal symptoms (mainly constipation) will decrease in the interventional group
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Famagusta
country: Cyprus
facility: Nezire
Study officials:
affiliation: Eastern Mediterranean University
name: Nezire Ince
role: STUDY_DIRECTOR
References:
Clinical trial NCT06620471: This is a Prospective Observational Study Assessing the Variation of Impedance Across the Different Tissues to Locate and Block Nerves When Preforming an Axillary Peripheral Nerve Block. the Results Would Enhance Precision of Needle Placement and Increase the Success Rate of the Block.
Official title: Assessing the Enhanced Precision: the Value of Impedance in Ultrasound-Guided Nerve Blocks, an Exploratory Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Impedance
Axillary Nerve Block
Lead sponsor: Lebanese American University
Sponsor class: OTHER
First posted: 2024-10-01
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: community sample

Brief summary: Impedance can have an impact on nerve block during loco-regional anesthesia, particularly when using techniques such as nerve stimulation or ultrasound guidance to locate and block specific nerves. Impedance refers to the resistance to electrical current flow within tissue, and it can affect the ability to stimulate nerves or visualize them using ultrasound. The aim of this research is to assess the impedance across different tissue type during an axillary peripheral nerve block (skin, fat, fascia, muscle, nerve). The results of this study would help clinicians performing nerve block to enhance the precision of needle placement, thus increase the success rate of nerve block and reduce adverse events such as intraneural or intravascular injections.


Eligibility criteria: Inclusion Criteria:

* Individuals aged 18 years to 90 years old
* No infection at the injection site
* Patient signed the study consent form
* No contraindications for nerve block
* No allergies to any of the drugs used
* Patient able to communicate effectively

Exclusion Criteria:

* Patients not meeting the inclusion criteria
* Patients with bleeding disorders or undergoing anticoagulation therapy
* Pregnant patients
* Patients with mental incapacity
* Any medical conditions posing severe risks during the procedure

Primary outcomes:
measure: Assess the impedance across different type of tissue during axillary nerve block
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Lebanese American University Rizk Hospital
Study officials:
References:
Clinical trial NCT01022671: Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy
Official title: Single-Arm, Open-label, Multicenter, Phase 2 Clinical Trial to Assess the Efficacy and Safety of Single-Agent Camtobell Inj.(Belotecan) Administered on A Weekly Schedule in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Previously Treated With Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Belotecan
Camtobell inj
NSCLC
Lead sponsor: Chong Kun Dang Pharmaceutical
Sponsor class: INDUSTRY
Collaborators: name: Asan Medical Center
name: Samsung Medical Center
name: Seoul National University Hospital
name: Ulsan University Hospital
First posted: 2009-12-01
Enrollment: 52
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.


Eligibility criteria: Inclusion Criteria:

* 19 Years and older
* Histologically or cytologically confirmed locally advanced or metastatic NSCLC(Stage IIIB or IV)
* ≥ one measureable or evaluable lesion, \<25% of the bone marrow had been irradiated
* prior platinum based chemotherapy
* ECOG PS ≤ 2
* Life expectancy \> 3 months
* Adequate organ function:

  * hematology: ANC ≥ 1.5×109/L, Platelet ≥ 100×109/L, hemoglobin ≥ 9.0g/dL
  * hepatic: total bilirubin ≤ 1.5×ULN, AST/ALT ≤ 2.0×ULN, ALP ≤2.0×ULN
  * renal: serum creatinine ≤ 1.5×ULN
* Signed a written informed consent

Exclusion Criteria:

* Active infection
* Symptomatic brain lesion
* Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix
* Severe concurrent diseases
* Prior anticancer therapy within 4 weeks before enroll
* Active pregnancy test

Primary outcomes:
measure: Objective Response Rate
timeFrame: every 2 cyc
Secondary outcomes:
measure: Overall Survival
timeFrame: 6 months after Last patient out
measure: Progression Free survival
timeFrame: 6 months after Last patient out
measure: Adverse event
timeFrame: every visit
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01566071: Ability to Drive of Early Stage Alzheimer Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alzheimer Disease
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2012-03-29
Enrollment: 60
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The main objectives of this study are:

* To evaluate the driving capacities in a population of elderly subjects with early stage Alzheimer Disease (AD) in a real-life situation.
* Define a typology of the main errors made in this population.
* Propose adaptive measures or technological aids that would make it possible for these patients to maintain their ability to drive a car while limiting risk.


Eligibility criteria: Inclusion Criteria:

The following subjects will be included and classified as " patients " :

* Age \> 70 years
* With established diagnosis of Alzheimer's disease as defined by DSM IV
* With MMSE score ≥ 24 (early-stage Alzheimer's disease)
* Holder of a valid driving license
* With regular driving activity (drives at least once per week)
* Informed consent provided.

The following subjects will be included and classified as " controls " :

* Age \> 70 years,
* Absence of cognitive impaired that interferes with their daily life at initial evaluation,
* Holder of a valid driving license,
* With regular driving activity (drives at least once per week),
* Informed consent provided.

Exclusion Criteria:

* Dementia syndrome(s) other than Alzheimer's disease,
* MMSE score \< 24
* Informed consent not provide

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Reims
country: France
facility: CHU de REIMS
Study officials:
affiliation: CHU de Reims
name: JEAN-LUC NOVELLA, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03967171: The Comparison of the Effect of Different Oxytocin Administrations on the Blood Loss During Cesarean Delivery
Official title: The Comparison of the Effect of Different Oxytocin Administrations on the Blood Loss During Cesarean Delivery: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cesarean Section Complications
Postpartum Hemorrhage
Blood Loss, Surgical
Blood Loss, Postoperative
Postoperative Pain
Atony, Uterine
Keywords: Oxytocin
cesarean section
uterine atony
Postpartum Hemorrhage
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2019-05-30
Enrollment: 101
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares the effect of starting intravenous oxytocin infusion early before uterine incision versus late after umbilical cord clamping on the blood loss during elective cesarean section

Detailed description: Postpartum hemorrhage (PPH) is still the major cause of maternal morbidity and mortality worldwide contributing to nearly 25% of direct maternal deaths. The average blood loss during cesarean section is 1000 ml which is nearly double the blood loss during vaginal delivery. Worldwide, the most commonly used uterotonic for the prevention of PPH is oxytocin. Several regimens of oxytocin have been tested during cesarean section with variable wanted (uterotonic) and unwanted (cardiovascular) effects. In the current study, we tested the hypothesis that initiating IV oxytocin infusion earlier before uterine incision would induce a rapid acceptable uterine contraction and minimize the intraoperative blood loss than the same dose administered after delivery of the fetus.

Eligibility criteria: Inclusion Criteria:

* single fetus at term \>37 weeks of gestational age

Exclusion Criteria:

* history of previous cesarean section
* history of previous uterine surgery
* multiple gestation, placenta previa, polyhydramnious, fetal macrosomia
* women at high risk for uterine atony such as anemia (Hb \< 8 gm/dL)
* uterine atony history
* gestational diabetes mellitus, gestational hypertension, preeclampsia, current or previous history of heart disease, liver, renal disorders or known coagulopath

Primary outcomes:
measure: blood loss during elective cesarean section
timeFrame: 2 hours
Secondary outcomes:
measure: postoperative blood loss
timeFrame: 24 hours
Other outcomes:
measure: postoperative pain score
timeFrame: 24 hours
measure: neonatal wellbeing
timeFrame: 2 hours
Locations:
city: Istanbul
country: Turkey
facility: Bezmialem Vakıf University Hospital
Study officials:
References:
Clinical trial NCT00823771: A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment
Official title: A Pilot Study in the Transfer of Follow-up Reviews to the General Practitioner for Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Prostate Cancer
Lead sponsor: Barwon Health
Sponsor class: OTHER_GOV
First posted: 2009-01-16
Enrollment: 107
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men approximately six months post-completion of radical radiotherapy treatment for prostate cancer who have not experienced significant treatment toxicities or disease progression.

Brief summary: This is a pilot study assessing the role of the general practitioner in performing follow-up reviews on men who have recently completed radical radiotherapy for prostate cancer. This will be measured primarily by assessing any changes to the patient's health-related quality of life which will be evaluated by the completion of questionnaires by the participant at each review visit. The study aims to confirm that patient outcome is identical, independent of whether follow-up is performed by a specialist or the patient's General Practitioner.


Eligibility criteria: Inclusion Criteria:

* Men with a tumour T1-3 stage prostate cancer and have had radical radiotherapy with curative intent
* Are between six and twelve months post-treatment completion
* Have completed all treatment for prostate cancer (including hormonal deprivation therapy)
* Have no evidence of metastatic disease
* ECOG performance status of between 0-1
* Remains willing to comply with study requirements
* Has maintained contact with an individual general practitioner

Exclusion Criteria:

* Persistent complications resulting from treatment defined as a minimum Grade 3 treatment toxicity
* Unable to complete self-administered questionnaires
* Are currently enrolled in a study that requires specialist follow-up
* Life expectancy of less than 6 months
* Surgery to remove the prostate
* Evidence of biochemical failure

Primary outcomes:
measure: To evaluate the patient's health-related quality of life that will be assessed by the patient completing self-administered questionnaires
timeFrame: QOL questionnaires will be asked to be completed at baseline, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 months
Secondary outcomes:
Other outcomes:
Locations:
city: Geelong
country: Australia
facility: Andrew Love Cancer Centre
state: Victoria
Study officials:
affiliation: Barwon Health
name: Rodney Lynch, BMedSc, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02101671: Inadequate Emergence After Laparoscopic Surgery in Trendelemburg Position
Official title: Inadequate Emergence After Anaesthesia in Laparoscopic Surgery in Trendelemburg Position
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Delayed Emergence From Anesthesia
Delirium, Cause Unknown
Confusion
Disorientation on Emergence
Keywords: agitation
anaesthesia
laparoscopy
surgery
delirium
sedation
emergence
steep
trendelemburg
position
delayed
Confusion
Disorientation
Lead sponsor: Corporacion Parc Tauli
Sponsor class: OTHER
First posted: 2014-04-02
Enrollment: 140
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient undergone surgery

Brief summary: The purpose of this study is to determinate if the patients submitted to laparoscopic surgery in trendelemburg position develope more inadequate anaesthesic emergence than patients submitted to laparoscopic surgery in other positions.


Eligibility criteria: Inclusion Criteria:

* laparoscopic surgery
* general anaesthesia
* trendelemburg positioning
* extubated in the operatory theater

Exclusion Criteria:

* unable of communicate
* dementia
* psychiatric history
* neurosurgery
* alchohol and drugs addictions

Primary outcomes:
measure: Inadequate emergence after anaesthesia
timeFrame: 10 minutes after the arrival of the patient in the postsurgical unit
Secondary outcomes:
Other outcomes:
Locations:
city: Sabadell
country: Spain
facility: Anaesthesia and Reanimation Department, Hospital Parc Tauli
state: Barcelona
Study officials:
affiliation: Corporacion Parc Tauli
name: Morena Basso
role: PRINCIPAL_INVESTIGATOR
References: